Regnum RGMP · USD

Its shares trade under the ticker RGMP. It has been listed since 15 March 2019. In the fiscal year to 31 December 2021, it reported revenue of $9,000 and a net loss of $270,000. At that date it held total assets of $1.5m and shareholders' equity of −$379,823.

Regnum Corp. engages in the business of developing and commercializing therapeutics that treat rare and infectious diseases. The company is headquartered in New York City, New York. The company went IPO on 2019-03-15. The firm's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. Leronlimab is a monoclonal antibody. The target of leronlimab is the immunologic receptor CCR5. Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells. The leronlimab antibody belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. Leronlimab blocks HIV from entering a cell by binding to a molecule called CCR5 referred to as R5 strains, attach as part of HIVs entry into a cell.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Robert StubblefieldChief Financial Officer, Treasurer$45,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.